ADRs End Lower; Barinthus Biotherapeutics PLC Declines 30%

Dow Jones11/16 05:31

Barinthus Biotherapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Phase 2b HBV003 Clinical Trial.

Benzinga11/16 02:19

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

MT Newswires11/16 01:27

Arbutus And Barinthus Bio Report IM-PROVE II Trial Data Showing Nivolumab Boosts HBsAg Loss Rates In Chronic Hepatitis B Patients; 23% Achieve HBsAg Loss By Week 48 With Imdusiran, VTP-300, And Low-Dose Nivolumab

Benzinga11/16 00:02

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

GlobeNewswire11/16 00:02

Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

Benzinga11/06 21:18